News

The novel chemical entity XEN402 is designed to inhibit the SCN9A sodium channel. Teva Pharmaceutical Industries has exclusive worldwide license to XEN402 that earlier demonstrated to relieve from

Ideal for both upstream and downstream processing, the HyPerforma SUM DS 300 system enables producers to meet liquid production demands with a minimal capital investment. The HyPerforma SUM

As per the development collaboration, Activaero’s FAVORITE (Flow and Volume Controlled Inhalation Technology) inhalation approach will be used along with an undisclosed compound to treat PH. The program

The study will assess the safety and efficacy profile of a once-daily oral combination regimen comprising Bristol-Myers’ investigational NS5A replication complex inhibitor daclatasvir and Merck’s investigational NS3/4A protease

As per the agreement, Phyto Nutricare will pay a one-time license fee of $2m to Plandai and then a recurring payment of 5% from the future profits of

As per the agreement, DSM will initiate the development activities for DecImmune’s lead monoclonal antibody program. DecImmune is developing an antibody-based therapeutic that can prevent tissue damage and

The DSM plant was built with the cooperation of the Queensland and Commonwealth Governments of Australia. DSM Biologics president Karen King said that the company’s partnership with the

MINASTRIN 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) is indicated for use by females of reproductive age for the prevention of pregnancy. A

The extension of the collaboration that was initiated in May 2010 further validates Evotec’s technology platform, according to the company. Evotec chief operating officer Dr Mario Polywka said,